Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

[1]  A. G. Pedersen,et al.  Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non‐target sites, for DAA‐based treatment and retreatment outcome , 2020, Journal of viral hepatitis.

[2]  J. Bukh,et al.  Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity , 2020, Antimicrobial Agents and Chemotherapy.

[3]  J. Bukh,et al.  Mutations identified in the HCV polymerase of ribavirin treated chronic hepatitis C patients cause resistance and affect viral replication fidelity. , 2020, Antimicrobial agents and chemotherapy.

[4]  J. McLauchlan,et al.  An interferon lambda 4-associated variant in the hepatitis C virus RNA polymerase affects viral replication in infected cells , 2020, The Journal of general virology.

[5]  E. Domingo,et al.  Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. , 2019, Antiviral research.

[6]  E. Barnes,et al.  Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir , 2019, Gastroenterology.

[7]  L. Cuypers,et al.  Next-generation sequencing for the clinical management of hepatitis C virus infections: does one test fits all purposes? , 2019, Critical reviews in clinical laboratory sciences.

[8]  Kinh Nguyen Van,et al.  Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. , 2019, The lancet. Gastroenterology & hepatology.

[9]  J. Pawlotsky,et al.  Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r , 2019, Hepatology.

[10]  J. Bukh,et al.  Full-Length Open Reading Frame Amplification of Hepatitis C Virus. , 2018, Methods in molecular biology.

[11]  P. Simmonds,et al.  Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors , 2018, Hepatology.

[12]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[13]  J. Bukh,et al.  HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. , 2018, Gastroenterology.

[14]  P. Simmonds,et al.  Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors. , 2018 .

[15]  M. Buti,et al.  Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. , 2017, Gastroenterology.

[16]  T. Hassanein,et al.  Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial , 2018, Hepatology.

[17]  J. Hughes,et al.  Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries. , 2017, Journal of hepatology.

[18]  H. Mo,et al.  Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. , 2017, Journal of hepatology.

[19]  C. Stedman,et al.  The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment , 2017, Hepatology communications.

[20]  C. Spencer,et al.  Genome-to-genome analysis highlights the impact of the human innate and adaptive immune systems on the hepatitis C virus , 2017 .

[21]  H. Mo,et al.  Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. , 2017, Journal of Hepatology.

[22]  F. Ceccherini‐Silberstein,et al.  Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[23]  Alexander M. Fraser,et al.  Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank , 2016, International journal of epidemiology.

[24]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2016. , 2017, Journal of hepatology.

[25]  J. Bukh,et al.  Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir. , 2016, Gastroenterology.

[26]  H. Mo,et al.  L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. , 2016, The Journal of infectious diseases.

[27]  X. Didelot,et al.  Bayesian Inference of the Evolution of a Phenotype Distribution on a Phylogenetic Tree , 2016, Genetics.

[28]  T. Asselah,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.

[29]  E. Barnes,et al.  Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. , 2015, Gastroenterology.

[30]  David Bonsall,et al.  ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens , 2015, F1000Research.

[31]  P. Klenerman,et al.  The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design , 2015, Gut.

[32]  L. Foster.  Active Ageing: Voluntary Work by Older People in Europe, Andrea Principi, Per H. Jensen, and Giovanni Lamura, eds. , 2015 .

[33]  L. Naeger,et al.  Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir , 2015, Hepatology.

[34]  N. Parkin,et al.  Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  Riina Salupere,et al.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.

[36]  F. Penin,et al.  Determinants for Membrane Association of the Hepatitis C Virus NS2 Protease Domain , 2014, Journal of Virology.

[37]  S. So,et al.  In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. , 2014, The Journal of infectious diseases.

[38]  Alexandros Stamatakis,et al.  RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies , 2014, Bioinform..

[39]  S. Zeuzem,et al.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2014, Journal of hepatology.

[40]  Daniel J. Wilson,et al.  A Modified RNA-Seq Approach for Whole Genome Sequencing of RNA Viruses from Faecal and Blood Samples , 2013, PLoS ONE.

[41]  T. Liang,et al.  The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C , 2012, Antiviral chemistry & chemotherapy.

[42]  Jieyun Jiang,et al.  Cell Culture-Adaptive Mutations Promote Viral Protein-Protein Interactions and Morphogenesis of Infectious Hepatitis C Virus , 2012, Journal of Virology.

[43]  D. Feigelstock,et al.  Selection of hepatitis C virus resistant to ribavirin , 2011, Virology Journal.

[44]  F. Penin,et al.  Nonstructural protein 3‐4A: the Swiss army knife of hepatitis C virus , 2011, Journal of viral hepatitis.

[45]  F. Penin,et al.  NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly , 2011, PLoS pathogens.

[46]  M. Otto,et al.  PSI-7851, a Pronucleotide of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication , 2010, Antimicrobial Agents and Chemotherapy.

[47]  F. Penin,et al.  Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3 , 2009, Proceedings of the National Academy of Sciences.

[48]  Zhuyan Guo,et al.  Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. , 2007, Journal of medicinal chemistry.

[49]  C. Rice,et al.  Structure of the catalytic domain of the hepatitis C virus NS2-3 protease , 2006, Nature.

[50]  Toshiaki Maruyama,et al.  Complete Replication of Hepatitis C Virus in Cell Culture , 2005, Science.

[51]  C. Rice,et al.  A second hepatitis C virus-encoded proteinase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[52]  N. Kato,et al.  Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus , 1993, Journal of virology.

[53]  C. Dolea,et al.  World Health Organization , 1949, International Organization.